← Back to Screener
Champions Oncology, Inc. (CSBR)
Price$6.10
Favorite Metrics
Price vs S&P 500 (26W)-9.49%
Price vs S&P 500 (4W)0.18%
Market Capitalization$85.40M
P/E Ratio (Annual)18.17x
All Metrics
P/CF (Annual)11.56x
Book Value / Share (Quarterly)$0.31
P/TBV (Annual)17.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)5.06%
Cash Flow / Share (Quarterly)$0.27
Price vs S&P 500 (YTD)-13.02%
Gross Margin (TTM)45.88%
Net Profit Margin (TTM)-3.94%
EPS (TTM)$-0.17
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.17
Revenue Growth (5Y)12.13%
EPS (Annual)$0.33
ROI (Annual)117.76%
Gross Margin (Annual)50.15%
Net Profit Margin (5Y Avg)-2.83%
Cash / Share (Quarterly)$0.51
P/E Basic Excl Extra (TTM)32.38x
Revenue Growth QoQ (YoY)-2.82%
P/E Normalized (Annual)18.17x
ROA (Last FY)14.53%
Revenue Growth TTM (YoY)-1.10%
EBITD / Share (TTM)$-0.07
ROE (5Y Avg)-3.36%
Operating Margin (TTM)-4.53%
Cash Flow / Share (Annual)$0.51
P/B Ratio19.94x
P/B Ratio (Quarterly)23.12x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.35x
Net Interest Coverage (TTM)-6.62x
ROA (TTM)-7.51%
EPS Growth QoQ (YoY)-64.35%
EV / EBITDA (TTM)20.29x
EPS Incl Extra (Annual)$0.33
Current Ratio (Annual)0.94x
Quick Ratio (Quarterly)0.93x
3-Month Avg Trading Volume0.01M
52-Week Price Return-15.80%
EV / Free Cash Flow (Annual)11.20x
P/E Incl Extra (TTM)32.38x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.70
P/S Ratio (Annual)1.50x
Asset Turnover (Annual)1.76x
52-Week High$9.63
Operating Margin (5Y Avg)-2.86%
EPS Excl Extra (Annual)$0.33
CapEx CAGR (5Y)-29.41%
26-Week Price Return-5.50%
Quick Ratio (Annual)0.88x
13-Week Price Return-8.85%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)0.98x
Enterprise Value$78.382
Revenue / Share Growth (5Y)8.03%
Asset Turnover (TTM)1.91x
Book Value / Share Growth (5Y)7.27%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)50.00x
Pretax Margin (Annual)8.12%
Cash / Share (Annual)$0.71
3-Month Return Std Dev53.95%
Gross Margin (5Y Avg)47.26%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)-39.38%
ROE (Last FY)124.63%
Net Interest Coverage (Annual)-2.54x
EPS Basic Excl Extra (Annual)$0.33
P/FCF (TTM)11.21x
Receivables Turnover (TTM)4.16x
EV / Free Cash Flow (TTM)20.54x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.17
Receivables Turnover (Annual)5.49x
ROI (TTM)-55.72%
P/S Ratio (TTM)1.47x
Pretax Margin (5Y Avg)-2.80%
Revenue / Share (Annual)$3.99
Tangible BV / Share (Annual)$0.70
Forward P/E51.50x
Free OCF CAGR (5Y)58.93%
Price vs S&P 500 (52W)-45.63%
P/E Ratio (TTM)32.38x
Year-to-Date Return-10.56%
5-Day Price Return7.48%
EPS Normalized (Annual)$0.33
ROA (5Y Avg)-5.20%
Net Profit Margin (Annual)8.26%
Month-to-Date Return7.48%
Cash Flow / Share (TTM)$-0.32
EBITD / Share (Annual)$0.43
EPS Growth (3Y)104.02%
Operating Margin (Annual)8.00%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)19.44x
ROI (5Y Avg)-4.55%
P/E Excl Extra (TTM)32.38x
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-0.17
P/TBV (Quarterly)17.39x
P/B Ratio (Annual)26.21x
Inventory Turnover (TTM)50.40x
Pretax Margin (TTM)-4.14%
Book Value / Share (Annual)$0.27
Price vs S&P 500 (13W)-9.54%
Beta0.41x
P/FCF (Annual)12.21x
Revenue / Share (TTM)$4.17
ROE (TTM)-58.02%
52-Week Low$5.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CSBRChampions Oncology, Inc. | 1.47x | -1.10% | 45.88% | — | $6.10 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Champions Oncology provides precision medicine technology for oncology drug development and personalized cancer treatment. Its Personalized Oncology Solutions segment delivers tumor-specific genomic data to physicians for treatment customization, while its Translational Oncology Solutions segment supports pharmaceutical companies with tumor specimens and research services for drug development. The company generates revenue primarily through research services to both healthcare providers and biopharma clients.